Julian Harrison
Stock Analyst at BTIG
(1.83)
# 2,989
Out of 4,784 analysts
41
Total ratings
33.33%
Success rate
-7.05%
Average return
Main Sectors:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $8.46 | +372.81% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $14.54 | +188.86% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $10.79 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $18.95 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.32 | +581.82% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.59 | +403.14% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $1.70 | +370.59% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $14.44 | +322.44% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $2.93 | +411.95% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $15.09 | +65.67% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $48.88 | +4.34% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.53 | - | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $6.43 | +568.74% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $17.94 | +122.97% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $9.23 | +127.52% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $39.72 | +8.26% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $1.91 | +109.42% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.54 | +27,672.64% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $39.86 | -9.68% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $306.97 | - | 2 | Feb 11, 2022 |
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $8.46
Upside: +372.81%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $14.54
Upside: +188.86%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.79
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $18.95
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.32
Upside: +581.82%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.59
Upside: +403.14%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $1.70
Upside: +370.59%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $14.44
Upside: +322.44%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $2.93
Upside: +411.95%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $15.09
Upside: +65.67%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $48.88
Upside: +4.34%
Jun 17, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.53
Upside: -
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $6.43
Upside: +568.74%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $17.94
Upside: +122.97%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $9.23
Upside: +127.52%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $39.72
Upside: +8.26%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $1.91
Upside: +109.42%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.54
Upside: +27,672.64%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $39.86
Upside: -9.68%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $306.97
Upside: -